Compare McKesson Corporation (MCK) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Weibo Corp — how do they compare? McKesson Corporation trades at $824.07 (market cap $97.35B), while Weibo Corp trades at $8 (market cap $1.95B). The key difference: McKesson Corporation is far larger — about 49.9× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (7.63%). Which is the better fit depends on your goals.
| MCK | WB | |
|---|---|---|
Market Cap | $97.35B | $1.95B |
Sector | Health | Media |
52-Week High | $995.69 | $12.83 |
52-Week Low | $659.01 | $7.20 |
Enterprise Value | $101.98B | $1.22B |
Dividend Yield | 0.39% | 7.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
Weibo (WB) trades at $7.995, up 3.16% today, with a bullish technical signal from moving averages but overbought RSI readings. The stock shows deep value with a P/E of 5.42 and P/B of 0.49, supported by strong profitability including a 21.15% net margin. Recent earnings have slightly missed expectations, but revenue remains stable at $1.76 billion for 2025. News highlights Weibo's cash flow generation and inclusion in value stock lists, though competitive pressures are noted.
The outlook balances significant undervaluation against competitive and execution risks. The market cap of approximately $1.8 billion is below the net balance sheet value, suggesting a margin of safety. Key risks include user engagement challenges from rivals like Douyin and reliance on advertising revenue. Analyst sentiment is mixed but leans positive, with 45% recommending Buy. The stock presents a value opportunity contingent on successful business execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
